REG - Proteome Sciences - Grant of Options and PDMR/director shareholdings

Proteome SciencesAnnouncement

01/12/2022 16:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221201:nRSA3290Ia&default-theme=true

RNS Number : 3290I  Proteome Sciences PLC  01 December 2022

 
 

 

1 December 2022

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Grant of Options and PDMR/director shareholdings

 

Proteome Sciences announces that further to the announcement of Abdelghani
Omari's appointment as Chief Financial Officer on 18 August 2022 (the
"Appointment Announcement"), Mr Omari has today been granted 4,000,000 options
by the Company under the Company's share option scheme ("Options"). The
Options are to be issued at nominal value and will vest in three equal annual
tranches on 1 September 2023, 1 September 2024 and 1 September 2025. Each
Option is exercisable into one Ordinary Share and once vested, can be
exercised up until the 10th anniversary.

 

The Company notes that in the earlier Appointment Announcement, it said the
Options are exercisable at the closing price of the Company's ordinary shares
("Ordinary Shares") on the date the Options are granted. The Company
acknowledges that this statement was incorrect.

 

The Options granted to Mr Omari represent approximately 1.36 per cent of the
Company's current issued share capital. In total 24,471,000 Options are now
outstanding, representing approximately 8.30 per cent of the Company's current
issued share capital.

 

Further details and the information required in accordance with the
requirements of Article 19(3) of the Market Abuse Regulation No 596/2014 (as
retained and applicable in the UK pursuant to section 3 of the European Union
(Withdrawal) Act 2018) ("UK MAR") are set out at the end of this announcement.

 

 

For further information:

 Proteome Sciences plc
 Proteome Sciences plc
 Dr Mariola Soehngen, Chief Executive Officer         Tel: +44 (0)20 7043 2116
 Dr Ian Pike, Chief Scientific Officer
 Richard Dennis, Chief Commercial Officer
 Allenby Capital Limited (AIM Nominated Adviser & Broker)
 John Depasquale / Jeremy Porter (Corporate Finance)  Tel: +44 (0) 20 3328 5656

 Tony Quirke (Sales)

 

About Proteome Sciences plc. (www.proteomics.com (http://www.proteomics.com/)
)

Proteome Sciences plc is a specialist provider of contract proteomics services
to enable drug discovery, development and biomarker identification, and
employs proprietary workflows for the optimum analysis of tissues, cells and
body fluids.  SysQuant(®) and TMT(®)MS2 are unbiased methods for
identifying and contextualising new targets and defining mechanisms of
biological activity, while analysis using Super-Depletion and TMTcalibrator™
provides access to over 8,500 circulating plasma proteins for the discovery of
disease-related biomarkers. Targeted assay development using mass spectrometry
delivers high sensitivity, interference-free biomarker analyses in situations
where standard ELISA assays are not available.

 

The Company has its headquarters in Cobham, UK, with laboratory facilities in
Frankfurt, Germany.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.

 

The below notification is made in accordance with the requirements of UK MAR.

 

 1.      Details of the person discharging managerial responsibilities/person closely
         associated
 a)      Name:                                                         Abdelghani Omari
 2.      Reason for the notification
 a)      Position/status:                                              Chief Financial Officer
 b)      Initial notification/Amendment:                               Initial Notification
 3.      Details of the issuer, emission allowance market participant, auction
         platform, auctioneer or auction monitor
 a)      Name:                                                         Proteome Sciences Plc
 b)      LEI:                                                          213800Q62ICXANKU2986
 4.      Details of the transaction(s): section to be repeated for (i) each type of
         instrument; (ii) each type of transaction; (iii) each date; and (iv) each
         place where transactions have been conducted
 a)      Description of the financial instrument, type of instrument:  Ordinary Shares of 1p nominal value

         Identification code:                                          GB0003104196
 b)      Nature of the transaction:                                    Grant of options under the Proteome Sciences plc 2021 Long Term Share
                                                                       Incentive Plan to acquire ordinary shares of 1p each in Proteome Sciences plc
 c)      Price(s) and volume(s):

Price(s)  Volume(s)
                                                                       £0.01     4,000,000
 d)      Aggregated information:                                       Single transaction as in c) above

Average Price  Volume(s)
         ·    Aggregated volume:                                       £0.01          4,000,000

         ·    Price:
 e)      Date of the transaction:                                      1 December 2022
 f)      Place of the transaction:                                     N/A

d)

Aggregated information:

·    Aggregated volume:

·    Price:

Single transaction as in c) above

 Average Price  Volume(s)
 £0.01          4,000,000

e)

Date of the transaction:

1 December 2022

f)

Place of the transaction:

N/A

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHQFLFBLLLXFBQ